What are the key challenges in scaling up India's biotechnology sector despite recent growth?
Although India’s biotech industry is growing, it faces bottlenecks. This question seeks to understand the main obstacles that prevent the sector from expanding at a larger scale.
India’s biotechnology sector has witnessed significant growth in recent years, driven by advancements in research, increasing investments, and government initiatives. However, the sector continues to face several challenges that hinder its large-scale expansion and global competitiveness.
- Limited Funding and Investment: Access to venture capital and long-term funding remains inadequate, especially for start-ups and small enterprises. High-risk nature of biotech projects discourages private investment.
- Regulatory Hurdles: Complex and time-consuming regulatory processes for approvals, clinical trials, and product commercialization slow down innovation and market entry.
- Infrastructure Gaps: Lack of world-class laboratories, testing facilities, and bio-incubators restricts research and product development, particularly outside major cities.
- Shortage of Skilled Workforce: There is a deficit of trained scientists, technicians, and regulatory experts, which limits the sector’s ability to scale up and innovate.
- Intellectual Property (IP) Issues: Weak IP protection and enforcement discourage innovation and deter foreign collaborations and investments.
- Fragmented Ecosystem: Poor linkages between academia, industry, and research institutions lead to low technology transfer and commercialization rates.
- Limited Market Access: Challenges in accessing international markets due to non-tariff barriers, quality standards, and lack of global partnerships restrict export potential.
- Low Public Awareness: Limited understanding and acceptance of biotech products, especially in agriculture and healthcare, lead to resistance and slow adoption.
- High Cost of Technology: Import dependence for high-end equipment and reagents increases operational costs for biotech firms.
Answered
6 days ago